3.23

4.87% 0.15

After Hours: 3.20 -0.03 -0.93%

Editas Medicine Inc (EDIT)

Overview News Price History Option Chain Financials Why EDIT Down? Discussions Forecast

Editas Medicine Inc stock is traded at $3.23, with a volume of 1.39M. It is up +4.87% in the last 24 hours and up +16.61% over the past month. Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

Previous Close:

$3.08

Open:

$3.04

24h Volume:

1.39M

Relative Volume:

0.59

Market Cap:

$496.06M

Revenue:

$38.69M

Net Income/Loss:

$-108.95M

P/E Ratio:

-2.6421

EPS:

-1.2225

Net Cash Flow:

$-141.09M

1W Performance:

+2.22%

1M Performance:

+16.61%

6M Performance:

+47.49%

1Y Performance:

+28.17%

1-Day Range:

$3.04

$3.23

1-Week Range:

$2.98

$3.23

52-Week Range:

$1.66

$4.5372

Editas Medicine Inc Stock (EDIT) Company Profile

Name

Editas Medicine Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

617-401-9000

Address

11 HURLEY ST., CAMBRIDGE, MA

Employee

Twitter

@editasmed

Next Earnings Date

2026-08-11

Latest SEC Filings

EDIT's Discussions on Twitter

Compare EDIT vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EDIT Editas Medicine Inc	3.23	451.53M	38.69M	-108.95M	-141.09M	-1.2225
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-28-25	Initiated	H.C. Wainwright	Buy
Dec-16-24	Downgrade	JP Morgan	Neutral → Underweight
Dec-13-24	Downgrade	Chardan Capital Markets	Buy → Neutral
Dec-13-24	Downgrade	Stifel	Buy → Hold
Dec-13-24	Downgrade	Truist	Buy → Hold
Dec-11-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-25-24	Downgrade	BofA Securities	Buy → Underperform
Nov-06-24	Upgrade	Evercore ISI	In-line → Outperform
Nov-04-24	Downgrade	Raymond James	Outperform → Mkt Perform
Aug-08-24	Upgrade	BofA Securities	Neutral → Buy
May-09-24	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Oct-24-23	Upgrade	Citigroup	Neutral → Buy
Oct-18-23	Upgrade	JP Morgan	Underweight → Neutral
Oct-17-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-29-23	Upgrade	Stifel	Hold → Buy
Jun-12-23	Upgrade	Raymond James	Mkt Perform → Outperform
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight
Dec-13-22	Initiated	Citigroup	Neutral
Dec-06-22	Resumed	Credit Suisse	Neutral
Nov-18-22	Downgrade	Credit Suisse	Outperform → Neutral
Nov-18-22	Downgrade	Oppenheimer	Outperform → Perform
Sep-29-22	Initiated	BofA Securities	Neutral
Oct-19-21	Initiated	SVB Leerink	Mkt Perform
Sep-24-21	Initiated	Stifel	Hold
Sep-10-21	Upgrade	Oppenheimer	Perform → Outperform
Aug-09-21	Upgrade	Truist	Hold → Buy
Aug-05-21	Upgrade	Evercore ISI	Underperform → Outperform
Jun-04-21	Resumed	Robert W. Baird	Outperform
May-04-21	Initiated	RBC Capital Mkts	Sector Perform
Apr-16-21	Initiated	Goldman	Sell
Mar-22-21	Initiated	Credit Suisse	Outperform
Mar-01-21	Downgrade	Barclays	Overweight → Equal Weight
Feb-26-21	Downgrade	Truist	Buy → Hold
Jan-19-21	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Jan-07-21	Downgrade	Raymond James	Outperform → Mkt Perform
Dec-10-20	Upgrade	Wells Fargo	Equal Weight → Overweight
Nov-03-20	Initiated	Robert W. Baird	Underperform
Jun-18-20	Resumed	SunTrust	Buy
Feb-21-20	Initiated	Wells Fargo	Equal Weight
Apr-12-19	Initiated	Evercore ISI	Outperform
Oct-10-18	Initiated	Guggenheim	Neutral
Sep-21-18	Initiated	Raymond James	Outperform
May-15-18	Reiterated	Chardan Capital Markets	Buy
Feb-13-18	Initiated	CLSA	Underperform
Jan-23-18	Upgrade	SunTrust	Hold → Buy
Jul-14-17	Initiated	SunTrust	Hold
Mar-28-17	Initiated	Chardan Capital Markets	Buy
Aug-10-16	Upgrade	Jefferies	Hold → Buy
Jun-02-16	Initiated	Jefferies	Hold
Feb-29-16	Initiated	JMP Securities	Mkt Outperform
Feb-29-16	Initiated	JP Morgan	Neutral
Feb-29-16	Initiated	Morgan Stanley	Equal-Weight

View All

Editas Medicine Inc Stock (EDIT) Latest News

Sep 05, 2026

Seven Fleet Capital Management LP Takes Position in Editas Medicine, Inc. $EDIT - MarketBeat

Sep 05, 2026

Sep 04, 2026

Editas Medicine CSO Linda Burkly Sells 709 Shares to Cover RSU Tax Withholding - Kalkine Media

Sep 04, 2026

Editas Medicine CFO Amy Parison Sells Shares in September 2026 Under Pre-Set Plan - Kalkine Media

Sep 04, 2026

Editas Medicine (NASDAQ:EDIT) CEO Gilmore Neil O'neill Sells 5,124 Shares of Stock - MarketBeat

Sep 04, 2026

Editas Medicine CEO Gilmore Neil O'Neill Sells 5,124 Shares to Cover Tax Withholding on RSU Vesting - Kalkine Media

Sep 04, 2026

Editas Medicine (EDIT) CSO stock sale follows tax plan - Stock Titan

Sep 04, 2026

Pre-set plan triggers Editas (NASDAQ: EDIT) CFO share sale - Stock Titan

Sep 04, 2026

Editas Medicine (NASDAQ: EDIT) CEO sells 5,124 shares in tax-plan trade - Stock Titan

Sep 04, 2026

Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Sep 04, 2026

Sep 03, 2026

Editas Medicine (EDIT) Slides 1.3% to $3.04 as Support Level Comes into FocusRetracement Entry - vinanet.vn

Sep 03, 2026

Sep 02, 2026

EditasSlow Progress Doesn't Mean No Progress For In-Vivo Gene Editor (NASDAQ:EDIT) - Seeking Alpha

Sep 02, 2026

O'Neill plans another Editas (NASDAQ: EDIT) sale after June share trade - Stock Titan

Aug 31, 2026

Editas Medicine (EDIT) officer flags 700-share stock sale - Stock Titan

Aug 31, 2026

Editas Medicine stock holds steady as investors weigh latest gene editing progress - AD HOC NEWS

Aug 31, 2026

Aug 29, 2026

Nantahala Capital Management LLC Acquires Shares of 852,700 Editas Medicine, Inc. $EDIT - MarketBeat

Aug 29, 2026

Aug 28, 2026

EDIT Price History for Editas Medicine Stock - Barchart.com

Aug 28, 2026

Aug 27, 2026